



MEN

FIRST CANCER SITE GALLBLADDER

GALLBLADDER POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

COLECISTI POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	5866		8650		8650		5866		2588		509		164		5866	8650
Person-years ▶	9674		10871		1197		3149		4399		1499		627		9674	10871
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND GALLBLADDER	173	0.80	275	1.14	102	3.75	45	0.66	84	0.87	28	0.79	16	1.07	-4.35	3.01
HEAD AND NECK	8	0.97	8	0.86	0	0.00	2	0.74	4	1.06	2	1.57	0	0.00	-0.03	-0.12
ORAL CAVITY	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.20	-0.20
PHARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.17	-0.17
LARYNX	8	1.71	8	1.52	0	0.00	2	1.29	4	1.89	2	2.79	0	0.00	0.34	0.25
OESOPHAGUS	2	0.92	3	1.22	1	3.54	0	0.00	2	2.03	0	0.00	0	0.00	-0.02	0.05
STOMACH	14	1.06	28	1.86	14	7.70	3	0.68	6	1.02	4	1.89	1	1.17	0.08	1.19
COLON RECTUM	21	0.70	54	1.61	33	8.79	1	0.11	17	1.28	2	0.40	1	0.47	-0.91	1.88
COLON	15	0.73	39	1.69	24	9.35	1	0.16	11	1.20	2	0.58	1	0.68	-0.57	1.46
RECTUM	6	0.64	15	1.43	9	7.57	0	0.00	6	1.44	0	0.00	0	0.00	-0.34	0.41
LIVER	5	0.57	13	1.31	8	7.25	2	0.71	1	0.25	1	0.70	1	1.66	-0.39	0.28
GALLBLADDER	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.25	-0.26
PANCREAS	7	1.19	9	1.35	2	2.67	3	1.60	4	1.52	0	0.00	0	0.00	0.11	0.22
LUNG	33	0.87	41	0.96	8	1.65	8	0.65	14	0.82	7	1.14	4	1.59	-0.51	-0.16
SKIN MELANOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.29	-0.29
MESOTHELIOMA	1	0.91	1	0.81	0	0.00	0	0.00	0	0.00	1	5.43	0	0.00	-0.01	-0.02
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
SOFT TISSUE	1	1.38	1	1.23	0	0.00	0	0.00	0	0.00	1	8.32	0	0.00	0.03	0.02
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
PROSTATE	30	0.70	37	0.77	7	1.34	9	0.68	14	0.73	5	0.69	2	0.63	-1.32	-1.01
TESTIS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
KIDNEY AND RENAL PELVIS	8	1.25	22	3.06	14	18.01	4	1.99	4	1.39	0	0.00	0	0.00	0.16	1.36
BLADDER AND URINARY TRACT	19	0.77	26	0.94	7	2.23	9	1.14	6	0.55	0	0.00	4	2.38	-0.58	-0.16
URINARY BLADDER	19	0.81	26	0.98	7	2.33	9	1.19	6	0.57	0	0.00	4	2.49	-0.47	-0.05
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.11	-0.11
BRAIN AND CENTRAL NERVOUS SYSTEM	4	1.69	4	1.50	0	0.00	1	1.31	2	1.87	0	0.00	1	6.27	0.17	0.12
THYROID	1	1.15	2	2.07	1	10.00	0	0.00	1	2.54	0	0.00	0	0.00	0.01	0.10
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	3	0.50	4	0.60	1	1.36	0	0.00	1	0.38	2	2.04	0	0.00	-0.30	-0.25
MYELOMA	2	0.69	3	0.92	1	2.68	0	0.00	2	1.56	0	0.00	0	0.00	-0.09	-0.02
LEUKAEMIAS	4	0.79	6	1.05	2	3.00	0	0.00	4	1.78	0	0.00	0	0.00	-0.11	0.03
LYMPHOID LEUKAEMIAS	1	0.42	3	1.10	2	6.32	0	0.00	1	0.93	0	0.00	0	0.00	-0.14	0.03
MYELOID LEUKAEMIAS	2	0.88	2	0.78	0	0.00	0	0.00	2	1.98	0	0.00	0	0.00	-0.03	-0.05
OTHER LEUKAEMIAS	1	2.66	1	2.32	0	0.00	0	0.00	1	6.04	0	0.00	0	0.00	0.06	0.05
OTHER AND ILL DEFINED SITES	10	0.86	13	0.99	3	1.99	3	0.81	2	0.39	3	1.56	2	2.48	-0.16	-0.01

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

**FIRST CANCER SITE
GALLBLADDER**
**GALLBLADDER
POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

COLECISTI
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	9396	13811		13811		9396		3442		756		260		9396	13811
Person-years ▶	13942	15874		1932		4521		6012		2340		1069		13942	15874	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND GALLBLADDER	209	1.21	348	1.77	139	5.75	56	1.03	91	1.24	43	1.41	19	1.30	2.59	9.51
HEAD AND NECK	2	0.93	2	0.82	0	0.00	0	0.00	1	1.09	1	2.67	0	0.00	-0.01	-0.03
ORAL CAVITY	2	1.66	2	1.46	0	0.00	0	0.00	1	1.97	1	4.64	0	0.00	0.06	0.04
PHARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
OESOPHAGUS	1	1.09	2	1.91	1	7.48	0	0.00	1	2.61	0	0.00	0	0.00	0.01	0.06
STOMACH	9	0.76	30	2.20	21	11.77	1	0.27	5	1.01	3	1.42	0	0.00	-0.20	1.03
COLON RECTUM	43	1.49	75	2.28	32	7.86	12	1.33	21	1.74	5	0.96	5	1.98	1.02	2.65
COLON	33	1.59	54	2.28	21	7.18	10	1.55	15	1.73	5	1.33	3	1.63	0.88	1.91
RECTUM	10	1.24	21	2.28	11	9.58	2	0.79	6	1.76	0	0.00	2	2.93	0.14	0.74
LIVER	4	0.77	9	1.51	5	6.66	2	1.21	2	0.91	0	0.00	0	0.00	-0.09	0.19
GALLBLADDER	1	0.24	1	0.20	0	0.00	0	0.00	0	0.00	0	0.00	1	2.77	-0.23	-0.24
PANCREAS	18	2.35	20	2.29	2	1.84	6	2.54	8	2.52	2	1.41	2	2.84	0.74	0.71
LUNG	10	0.90	16	1.27	6	4.02	3	0.88	2	0.43	5	2.50	0	0.00	-0.08	0.22
SKIN MELANOMA	3	1.06	3	0.93	0	0.00	1	1.14	0	0.00	1	2.00	1	4.15	0.01	-0.01
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
SOFT TISSUE	0	0.00	1	1.25	1	10.35	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	0.01
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	56	1.38	85	1.85	29	5.25	16	1.24	18	1.03	17	2.45	5	1.53	1.11	2.45
CERVIX UTERI	2	0.94	4	1.65	2	6.45	1	1.41	1	1.09	0	0.00	0	0.00	-0.01	0.10
CORPUS UTERI	6	0.80	6	0.70	0	0.00	1	0.41	4	1.23	0	0.00	1	1.73	-0.11	-0.16
OVARY	23	4.32	29	4.78	6	8.09	7	4.11	13	5.72	3	3.27	0	0.00	1.27	1.44
KIDNEY AND RENAL PELVIS	3	0.72	17	3.59	14	25.10	2	1.55	1	0.56	0	0.00	0	0.00	-0.08	0.77
BLADDER AND URINARY TRACT	5	0.71	8	0.99	3	3.00	0	0.00	3	1.01	1	0.78	1	1.59	-0.15	0.00
URINARY BLADDER	4	0.61	7	0.93	3	3.23	0	0.00	2	0.73	1	0.84	1	1.72	-0.18	-0.03
URINARY TRACT	1	1.99	1	1.74	0	0.00	0	0.00	1	4.79	0	0.00	0	0.00	0.04	0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	1	0.40	1	0.35	0	0.00	0	0.00	0	0.00	1	2.26	0	0.00	-0.11	-0.12
THYROID	2	0.82	3	1.09	1	3.24	1	1.29	1	0.92	0	0.00	0	0.00	-0.03	0.02
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	2	0.31	7	0.94	5	5.59	0	0.00	2	0.72	0	0.00	0	0.00	-0.32	-0.03
MYELOMA	2	0.62	2	0.54	0	0.00	0	0.00	1	0.74	0	0.00	1	3.69	-0.09	-0.11
LEUKAEMIAS	6	1.29	9	1.69	3	4.45	3	2.03	2	1.03	1	1.20	0	0.00	0.10	0.23
LYMPHOID LEUKAEMIAS	1	0.48	1	0.42	0	0.00	0	0.00	1	1.15	0	0.00	0	0.00	-0.08	-0.09
MYELOID LEUKAEMIAS	3	1.40	6	2.45	3	9.88	2	2.98	0	0.00	1	2.59	0	0.00	0.06	0.22
OTHER LEUKAEMIAS	2	4.57	2	3.97	0	0.00	1	7.27	1	5.56	0	0.00	0	0.00	0.11	0.09
OTHER AND ILL DEFINED SITES	11	0.78	19	1.17	8	3.87	0	0.00	5	0.85	3	1.15	3	2.31	-0.23	0.17

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio